SNCA and Parkinson disease: Other therapy mechanisms leveraged by PD clinical trials include anti‐aggregation therapies such as myeloperoxidase inhibitor AZD3241 that are tested for effectiveness against the toxic aggregation of alpha‐synuclein, known as Lewy body formation.106